JP7311514B2 - インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド - Google Patents

インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド Download PDF

Info

Publication number
JP7311514B2
JP7311514B2 JP2020533876A JP2020533876A JP7311514B2 JP 7311514 B2 JP7311514 B2 JP 7311514B2 JP 2020533876 A JP2020533876 A JP 2020533876A JP 2020533876 A JP2020533876 A JP 2020533876A JP 7311514 B2 JP7311514 B2 JP 7311514B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
independently
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020533876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532585A5 (https=
JP2020532585A (ja
Inventor
リー，アンロン
チェン，シャオキ
ソン，ヤンタオ
Original Assignee
ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド filed Critical ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド
Publication of JP2020532585A publication Critical patent/JP2020532585A/ja
Publication of JP2020532585A5 publication Critical patent/JP2020532585A5/ja
Application granted granted Critical
Publication of JP7311514B2 publication Critical patent/JP7311514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
JP2020533876A 2017-08-30 2018-08-30 インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド Active JP7311514B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762552148P 2017-08-30 2017-08-30
US62/552,148 2017-08-30
US201862660565P 2018-04-20 2018-04-20
US62/660,565 2018-04-20
PCT/IB2018/056658 WO2019043634A2 (en) 2017-08-30 2018-08-30 CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS

Publications (3)

Publication Number Publication Date
JP2020532585A JP2020532585A (ja) 2020-11-12
JP2020532585A5 JP2020532585A5 (https=) 2021-10-07
JP7311514B2 true JP7311514B2 (ja) 2023-07-19

Family

ID=65527221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020533876A Active JP7311514B2 (ja) 2017-08-30 2018-08-30 インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド

Country Status (14)

Country Link
US (1) US11773132B2 (https=)
EP (1) EP3692048A4 (https=)
JP (1) JP7311514B2 (https=)
KR (1) KR102782200B1 (https=)
CN (1) CN111263767B (https=)
AU (1) AU2018323053A1 (https=)
BR (1) BR112020004047A2 (https=)
CA (1) CA3073919A1 (https=)
IL (1) IL272928A (https=)
MX (1) MX2020002303A (https=)
RU (1) RU2020112502A (https=)
SG (1) SG11202001847WA (https=)
TW (1) TWI808092B (https=)
WO (1) WO2019043634A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
ES2980374T3 (es) * 2018-03-08 2024-10-01 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
BR112020024605A2 (pt) 2018-06-01 2021-04-06 Eisai R&D Management Co., Ltd. Métodos para o tratamento de câncer de bexiga
CN112867727B (zh) * 2018-10-12 2024-05-17 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用
US12435104B2 (en) * 2019-07-25 2025-10-07 Beigene, Ltd. Cyclic dinucleotides as sting agonists
EP4114417A4 (en) * 2020-03-06 2024-08-14 OD Therapeutics Limited THERAPEUTIC AGENTS AND THEIR CONJUGATES
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
TWI901793B (zh) * 2020-10-20 2025-10-21 大陸商泰勵生物科技（上海）有限公司 多功能環二核苷酸及其用途
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500697A (ja) 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2017027646A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
JP2019509339A (ja) 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法
JP2020500862A (ja) 2016-11-25 2020-01-16 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE60332483D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
JPWO2005005450A1 (ja) 2003-07-15 2006-08-24 三井化学株式会社 環状ビスジヌクレオチドの合成方法
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2754127C (en) 2009-03-02 2017-04-18 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3546473B1 (en) * 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) * 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
EP3448393A1 (en) * 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
US11001605B2 (en) * 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
CN110167566A (zh) * 2016-12-21 2019-08-23 弗莱德哈钦森癌症研究中心 治疗实体瘤细胞和逃避变体的支架
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
CN110234403A (zh) * 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
CN112867727B (zh) * 2018-10-12 2024-05-17 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500697A (ja) 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2017027646A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
JP2019509339A (ja) 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法
JP2020500862A (ja) 2016-11-25 2020-01-16 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド

Also Published As

Publication number Publication date
US11773132B2 (en) 2023-10-03
WO2019043634A2 (en) 2019-03-07
CN111263767A (zh) 2020-06-09
BR112020004047A2 (pt) 2020-09-01
AU2018323053A1 (en) 2020-03-19
IL272928A (en) 2020-04-30
WO2019043634A3 (en) 2019-04-11
SG11202001847WA (en) 2020-03-30
CA3073919A1 (en) 2019-03-07
JP2020532585A (ja) 2020-11-12
TW201919650A (zh) 2019-06-01
TWI808092B (zh) 2023-07-11
KR102782200B1 (ko) 2025-03-17
RU2020112502A (ru) 2021-10-01
US20200331957A1 (en) 2020-10-22
CN111263767B (zh) 2023-07-18
KR20200058411A (ko) 2020-05-27
MX2020002303A (es) 2020-09-10
EP3692048A2 (en) 2020-08-12
RU2020112502A3 (https=) 2021-10-08
EP3692048A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
JP7311514B2 (ja) インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド
CA3168452A1 (en) Pyrimidin-4(3tf)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
JP2022509149A (ja) ピリミジンと５員窒素ヘテロ環の誘導体、その製造方法、およびそれらの医学的使用
AU2019288495B2 (en) Ectonucleotidase inhibitors and methods of use thereof
JP2022525010A (ja) 疾患の治療のための化合物、組成物、及び方法
AU2019222026A1 (en) Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CA3017524A1 (en) Cyclic di-nucleotide compounds and methods of use
JP6538656B2 (ja) ５’−ヌクレオチダーゼ阻害剤およびその治療的使用
JP2008531537A (ja) 化合物
KR20180112117A (ko) Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
CA2883426A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
CA2799764A1 (en) Mtor selective kinase inhibitors
JP7706795B2 (ja) Ｔｌｒ７アゴニスト
CN111989338A (zh) 修饰的环二核苷酸化合物
US20240066133A1 (en) Therapeutic agents and conjugates thereof
HK40022356A (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
HK40022356B (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
CA2760052C (en) Purine derivative and antitumor agent using same
CN115427051B (zh) 治疗剂及其结合物
HK40049659A (en) Tlr7 agonists
HK40049659B (en) Tlr7 agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230706

R150 Certificate of patent or registration of utility model

Ref document number: 7311514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350